Literature DB >> 20602174

Potential role of pioglitazone, caffeic acid and their combination against fatigue syndrome-induced behavioural, biochemical and mitochondrial alterations in mice.

Anil Kumar1, Aditi Vashist, Puneet Kumar.   

Abstract

Chronic fatigue is an illness characterised by persistent and relapsing fatigue, often accompanied by numerous neuropsychiatric problems, such as anxiety and depression. The aetiology of chronic fatigue remains unclear so far. However, recent studies suggested the involvement of oxidative stress in this chronic debilitating disease. Alternatively, antioxidants have also been reported to have beneficial effect against chronic fatigue-like conditions. Therefore, present study has been designed to explore the potential role of pioglitazone, caffeic acid and their combination against chronic fatigue-like condition in mice. In the experimental protocol, the mice were put on the running wheel apparatus for 6 min test session daily for 21 days which produced fatigue-like condition. The locomotor activity and anxiety levels were measured on 0, 8th, 15th and 22nd days. The brains were isolated on 22nd day immediately after the behavioural assessments, oxidative damage and mitochondrial enzyme complexes were then estimated subsequently. Three weeks pioglitazone (5 and 10 mg/kg) and caffeic acid (5 and 10 mg/kg) pretreatment significantly attenuated the chronic fatigue-like condition (restored running wheel activity, locomotor activity and reduced anxiety-like behaviour) as compared to that in control (chronic fatigue) animals. Further, pioglitazone (5 and 10 mg/kg) and caffeic acid (5 and 10 mg/kg) drug treatments for 3 weeks significantly attenuated oxidative damage (decreased lipid peroxidation, nitrite concentration, restored reduction in glutathione and catalase levels), altered mitochondrial enzymes complex (I, II and IV) activities and mitochondrial redox activity (MTT assay) when compared with control. Further, combination of lower dose of pioglitazone (5 mg/kg) and caffeic acid (5 mg/kg) showed significant synergism in their protective effect which was significant as compared to their effect per se. The present study highlights the potential role of pioglitazone, caffeic acid and their combination in the pathophysiology of chronic fatigue-like condition in mice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20602174     DOI: 10.1007/s10787-010-0048-2

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  66 in total

1.  Behavioral stimulation without alteration of beta and 5-HT receptors and adenylate cyclase activity in rat brain after chronic sertraline administration.

Authors:  C Tadokoro; Y Kiuchi; Y Yamazaki; K Nara; K Oguchi; K Kamijima
Journal:  Psychopharmacology (Berl)       Date:  1997-03       Impact factor: 4.530

2.  Prognosis in chronic fatigue syndrome: a prospective study on the natural course.

Authors:  J H Vercoulen; C M Swanink; J F Fennis; J M Galama; J W van der Meer; G Bleijenberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-05       Impact factor: 10.154

3.  Antioxidant status and lipoprotein peroxidation in chronic fatigue syndrome.

Authors:  B Manuel y Keenoy; G Moorkens; J Vertommen; I De Leeuw
Journal:  Life Sci       Date:  2001-03-16       Impact factor: 5.037

4.  Muscle fibre characteristics and lactate responses to exercise in chronic fatigue syndrome.

Authors:  R J Lane; M C Barrett; D Woodrow; J Moss; R Fletcher; L C Archard
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

5.  Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease.

Authors:  Pramod Kumar; Ravinder K Kaundal; Sandeep More; Shyam S Sharma
Journal:  Behav Brain Res       Date:  2008-10-15       Impact factor: 3.332

6.  A new behavioral test for antidepressant drugs.

Authors:  S Nomura; J Shimizu; M Kinjo; H Kametani; T Nakazawa
Journal:  Eur J Pharmacol       Date:  1982-09-24       Impact factor: 4.432

7.  Cytokine mRNA expression in patients with multiple sclerosis and fatigue.

Authors:  Peter Flachenecker; Irene Bihler; F Weber; M Gottschalk; Klaus V Toyka; Peter Rieckmann
Journal:  Mult Scler       Date:  2004-04       Impact factor: 6.312

8.  Skeletal muscle metabolism in the chronic fatigue syndrome. In vivo assessment by 31P nuclear magnetic resonance spectroscopy.

Authors:  R Wong; G Lopaschuk; G Zhu; D Walker; D Catellier; D Burton; K Teo; R Collins-Nakai; T Montague
Journal:  Chest       Date:  1992-12       Impact factor: 9.410

9.  Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress.

Authors:  Hitoshi Ishida; Makoto Takizawa; Sachihiko Ozawa; Yoko Nakamichi; Shinya Yamaguchi; Hidenori Katsuta; Toshiaki Tanaka; Masahiro Maruyama; Hiroshi Katahira; Katsuhiko Yoshimoto; Eiji Itagaki; Shinya Nagamatsu
Journal:  Metabolism       Date:  2004-04       Impact factor: 8.694

10.  Cognitive functioning in chronic fatigue syndrome and the role of depression, anxiety, and fatigue.

Authors:  Keryn Short; Marita McCabe; Greg Tooley
Journal:  J Psychosom Res       Date:  2002-06       Impact factor: 3.006

View more
  3 in total

1.  The possible association between Toxoplasma gondii infection and risk of anxiety and cognitive disorders in BALB/c mice.

Authors:  Hossein Mahmoudvand; Naser Ziaali; Iraj Aghaei; Vahid Sheibani; Saeideh Shojaee; Hossein Keshavarz; Mohammad Shabani
Journal:  Pathog Glob Health       Date:  2015       Impact factor: 2.894

2.  Modulation of the Nitrergic Pathway via Activation of PPAR-γ Contributes to the Neuroprotective Effect of Pioglitazone Against Streptozotocin-Induced Memory Dysfunction.

Authors:  Atish Prakash; Anil Kumar; Long Chiau Ming; Vasudevan Mani; Abu Bakar Abdul Majeed
Journal:  J Mol Neurosci       Date:  2015-02-18       Impact factor: 3.444

3.  A Possible Role for Pioglitazone in the Management of Depressive Symptoms in Metabolic Syndrome Patients (EPICAMP Study): A Double Blind, Randomized Clinical Trial.

Authors:  Hamidreza Roohafza; Pedram Shokouh; Masoumeh Sadeghi; Zahra Alikhassy; Nizal Sarrafzadegan
Journal:  Int Sch Res Notices       Date:  2014-08-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.